N-[(1R)-1-[3-(4-cyanophenyl)-8-cyclopropylimidazo[1,2-a]pyrazin-2-yl]ethyl]-N-[(1,1-dioxothian-4-yl)methyl]-2-[3-fluoro-4-(trifluoromethyl)phenyl]acetamide | 1190969-62-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-[(1R)-1-[3-(4-cyanophenyl)-8-cyclopropylimidazo[1,2-a]pyrazin-2-yl]ethyl]-N-[(1,1-dioxothian-4-yl)methyl]-2-[3-fluoro-4-(trifluoromethyl)phenyl]acetamide
• CAS: 1190969-62-0
• 化学式: C₃₃H₃₁F₄N₅O₃S
• 分子量: 653.7
• InChiKey: NQDZXGBUJMRXDE-HXUWFJFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  46
• 可旋转键数：
  8
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  117
• 氢给体数：
  0
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  3-氟-4-(三氟甲基)苯乙酸 、 在 N-甲基吗啉 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以70%的产率得到N-[(1R)-1-[3-(4-cyanophenyl)-8-cyclopropylimidazo[1,2-a]pyrazin-2-yl]ethyl]-N-[(1,1-dioxothian-4-yl)methyl]-2-[3-fluoro-4-(trifluoromethyl)phenyl]acetamide
  参考文献：
  名称：

  Imidazo-pyrazine derivatives as potent CXCR3 antagonists

  摘要：

  A general way of improving the potency of CXCR3 antagonists with fused hetero-bicyclic cores was identified. Optimization efforts led to the discovery of a series of imidazo-pyrazine derivatives with improved pharmacokinetic properties in addition to increased potency. The efficacy of the lead compound 21 is evaluated in a mouse lung inflammation model. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2009.07.021

文献信息

• Imidazo-pyrazine derivatives as potent CXCR3 antagonists
  作者：Xiaohui Du、Darin J. Gustin、Xiaoqi Chen、Jason Duquette、Lawrence R. McGee、Zhulun Wang、Karen Ebsworth、Kirk Henne、Bryan Lemon、Ji Ma、Shichang Miao、Emmanuel Sabalan、Timothy J. Sullivan、George Tonn、Tassie L. Collins、Julio C. Medina

  DOI：10.1016/j.bmcl.2009.07.021

  日期：2009.9

  A general way of improving the potency of CXCR3 antagonists with fused hetero-bicyclic cores was identified. Optimization efforts led to the discovery of a series of imidazo-pyrazine derivatives with improved pharmacokinetic properties in addition to increased potency. The efficacy of the lead compound 21 is evaluated in a mouse lung inflammation model. Published by Elsevier Ltd.